Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
17h
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
It was Donald Trump and Kamala Harris’s last chance to speak directly to the American people who have not yet decided who ...
María Camila Zarta tells TODAY.com that as a Colombian immigrant seeing the singer felt like he gave her a piece of her ...
1d
Ashby Kilgore was a bit apprehensive when she retired after 46 years in the public school system. “It was like, ‘What the ...
Martha Stewart is not big on sharing her feelings. To the millions who greedily gobbled up scuttlebutt about her legendary ...
Read on for updates about Heidi Klum's 2024 Halloween party including what she wore and other guests wore. Here are photos of ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback